Research Paper Volume 13, Issue 7 pp 10034—10057

A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients

The association between m6A regulatory gene risk signature and tumor immunity of LADC patients. (A) Boxplot shows differences in immune scores, stromal scores and tumor purity between high-risk and low-risk LADC patient groups. (B) Spearman analysis shows the correlation between risk scores and immune microenvironment parameters such as the immune scores, stromal scores and tumor purity. (C) Relative proportions of infiltrating immune cell types in the high-risk and low-risk LADC patient groups. (D) Boxplot shows differences in expression levels of the immune checkpoint proteins between high-risk and low-risk LADC patient groups. (E) Spearman analysis shows correlation between TMB and risk scores. (F) Violin plot shows differences in TMB between high-risk and low-risk LADC patient groups. (G) Box plot shows the response to immune checkpoint therapy in high-risk and low-risk LADC patient groups.

Figure 9. The association between m6A regulatory gene risk signature and tumor immunity of LADC patients. (A) Boxplot shows differences in immune scores, stromal scores and tumor purity between high-risk and low-risk LADC patient groups. (B) Spearman analysis shows the correlation between risk scores and immune microenvironment parameters such as the immune scores, stromal scores and tumor purity. (C) Relative proportions of infiltrating immune cell types in the high-risk and low-risk LADC patient groups. (D) Boxplot shows differences in expression levels of the immune checkpoint proteins between high-risk and low-risk LADC patient groups. (E) Spearman analysis shows correlation between TMB and risk scores. (F) Violin plot shows differences in TMB between high-risk and low-risk LADC patient groups. (G) Box plot shows the response to immune checkpoint therapy in high-risk and low-risk LADC patient groups.